# US 2013/0295146 A1 · Composition for Improving Membrane Composition and Functioning of Cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0295146 A1
- Document ID: US20130295146A1
- Status: Published application
- Kind: A1
- Application number: 13/933,172
- Filed: 2013-07-02
- Published: 2013-11-07
- Earliest claimed: 2005-12-23
- Assignees: N.V. Nutricia
- Inventors: Robert Johan Joseph HAGEMAN; Mattheus Cornelis DE WILDE; Patrick Joseph Gerardus Hendrikus KAMPHUIS
- Web page: https://patentgrep.com/patent/US20130295146A1

## CPC

- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A23L 33/12: Fatty acids or derivatives thereof
- A23L 33/15: Vitamins
- A23L 33/16: Inorganic salts, minerals or trace elements
- A23L 33/17: Amino acids, peptides or proteins
- A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula}
- A61K 8/361: {Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof}
- A61K 31/185: Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids (hydroxamic acids A61K31/16; peroxy acids A61K31/327)
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/20: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K 33/24: Heavy metals; Compounds thereof
- A61K 33/32: Manganese; Compounds thereof
- A61K 35/20: Milk; Whey; Colostrum
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/06: Antiarrhythmics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61Q 19/00: Preparations for care of the skin
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises: a) a lipid fraction comprising at least one of docosahexaneoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA); b) a protein fraction comprising proteinaceous material from non-human origin which provide at least cysteine and/or taurine; and c) a mineral fraction comprising at least one of manganese and molybdene, the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery.

## Claims

### Claim 1

Use of:
a) a lipid fraction comprising at least one of docosahexaneoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA);
b) a protein fraction comprising proteinaceous material from non-human origin which provide at least cysteine and/or taurine; and
c) a mineral fraction comprising at least one of manganese and molybdenum
in the manufacture of a nutriceutical or pharmaceutical composition for the treatment or prevention of neurological disorders, the improvement of the function of nerve cells, the decrease in the formation of plaques, neuropathies, and/or the improvement of function of the nerve system.

### Claim 2 (depends on 1)

The use according to claim 1, characterized in that the composition further comprises a nucleotide fraction, selected from the group consisting of nucleobases like uridine, cytidine, adenine, guanidine, thymidine, their phosphorylated forms, in particular the mono-phosphorylated forms such as uridine monophosphate, but also adenosine and guanosine, nucleotides and nucleosides.

### Claim 3 (depends on 1)

The use according to claim 1, wherein the composition further comprises a digestible carbohydrate fraction, preferably a source of galactose and/or ribose.

### Claim 4 (depends on 1)

The use according to claim 1, wherein the composition comprises a lipid fraction from originating from a dairy product, from eggs or from the endosperm of plant seeds or beans.

### Claim 5 (depends on 1)

The use according to claim 1, wherein the lipid fraction comprises fat globules having a size of 0,001-10 μm.

### Claim 6 (depends on 1)

The use according to claim 1, characterized in that the composition comprises a protein fraction which provides cysteine and/or taurine and a lipid fraction, and wherein the composition provides per daily dose:
d) 400 to 3300 mg of DHA+DPA+EPA;
e) a Uridine source which provides 0.08-3/324 Mol uridine,
f) and wherein the product provides per 100 kJ 2-40 ug molybdenum and more than 0.0238 mg manganese.

### Claim 7

A composition for improving cognitive function in elderly subjects, the composition having an energy content of 50-120 kcal, a protein content of 1-10 g, a lipids content of lipids 1-5 g, and a content of digestible carbohydrates of 4-20 g, which composition comprises:
g) 1000-2000 mg DHA+DPA+EPA
h) 30-280 mg cysteine or taurine
i) 100-1000 mg phospholipids
j) 0.5-3 mg vitamin B6
k) 50-500 ug folic acid
l) 1-30 ug vitamin B12
m) 0.07-2 mg manganese; and
n) 0.07-2 mg molybdenum.

### Claim 8

A ready-to-drink liquid for Alzheimer patients that comprises per 100 ml of the following:
Energy
100
kcal
Protein
3.06 g (casein, whey 80/20)
Carbohydrates
13.3 g (maltodextrins, sucrose)
Fat
3.73 g (fish oil, phospholipids)
comprising 0.96 g DHA and 0.24 g EPA
Uridine
0.5 g (disodium salt)
monophosphate
Choline
0.32
g
Vitamin E
32 mg alpha-tocopherol
Vitamin C
64
mg
Selenium
48
μg
Vitamin B6
0.8
mg
Folic acid
0.32
mg
Vitamin B12
2.4
μg
Magnesium
20
mg
Zinc
1.2
mg
Manganese
0.3
mg
Molybdenum
10
μg

### Claim 9

A powdered anti-allergic infant formulation, which comprises after fresh reconstitution of 15.4 g powder per 100 ml water:
an energy content of 64-80 kcal, and:
a protein fraction of 1.0-2.0 g, which is based exclusively on free amino acids or their salts, and which comprises at least 2 wt % cysteine and 0.2 wt % taurine;
a lipids fraction of 2-4 g, which comprises 2 wt % DHA based on the total sum of fatty acids, wherein the lipid ingredients include 5-40 wt % buttermilk fat and 0.5-8 wt % egg lipids including lecithin;
a nucleotide fraction of 1-40 mg, which comprises a mixture of UMP and yeast extract;
a mineral fraction of 76.3-1300 μg comprising 65-1000 μg manganese included as salt, in particular MgSO4, and 2.3-300 μg molybdenum included as salt, in particular molybdate salt; and
20-200 mg choline, included as choline salt, in particular choline bitartrate.

### Claim 10 (depends on 1)

The use of a composition according to claim 1 for improving the function of a mammalian cell, selected from the group of nerve cells, immune cells, stem cells, bone marrow cells and erythrocytes.

### Claim 11 (depends on 1)

The use of a composition according to claim 1 for improving memory function in a mammal.

### Claim 12 (depends on 1)

The use of a composition according to claim 1 for stimulating immune function in a mammal.

### Claim 13 (depends on 1)

The use of a composition according to claim 1 for preventing obesity in a mammal.

### Claim 14 (depends on 1)

The use of a composition according to claim 1 for treating chronic inflammation diseases, such as arthritis, hepatitis, pancreatitis and bronchitis, COPD, arrhythmias, heart failures, tumors and diabetes.

### Claim 15 (depends on 1)

The use of a composition according to claim 1 for the manufacture of a medicament for the treatment of at least one indication selected from the group of dementia, such as Alzheimer's disease, neuropathies, depressed immune function, allergy, anaemia, obesitas, diabetes, autoimmune diseases, arrhythmias, heart failures, tumors, COPD, bronchitis, arthritis, hepatitis, chronic inflammation and rheumatoid diseases
